Universal Health Realty Income Trust
Change company Symbol lookup
Select an option...
UHT Universal Health Realty Income Trust
BBVA Banco Bilbao Vizcaya Argentaria SA
RILY B Riley Financial Inc
WTS Watts Water Technologies Inc
MMM 3M Co
ADTH AdTheorent Holding Company Inc
GAZ iPath? Series B Bloomberg Natural Gas Subindex Total ReturnSM ETN
SNAP Snap Inc
FNB FNB Corp
CNFR Conifer Holdings Inc
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Small Cap Blend
Company profile

Universal Health Realty Income Trust is a real estate investment trust. The Company invests in health care and human service related facilities, including acute care hospitals, behavioral health care hospitals, specialty facilities, free-standing emergency departments, childcare centers, and medical/office buildings. The Company’s portfolio consists of approximately 75 real estate investments or commitments located in approximately 21 states in the United States consisting of approximately six hospital facilities, including three acute care and three behavioral health care; approximately fifty-eight medical/office buildings; approximately four free-standing emergency departments; and approximately four preschool and childcare centers, and approximately three specialty facilities. The Company’s portfolio includes McAllen Medical Center, Wellington Regional Medical Center, Canyon Creek Behavioral Health and Clive Behavioral Health Hospital.

Closing Price
$57.26
Day's Change
-0.19 (-0.33%)
Bid
--
Ask
--
B/A Size
--
Day's High
57.33
Day's Low
56.01
Volume
(Heavy Day)
Volume:
73,703

10-day average volume:
37,719
73,703

Novavax says Phase 3 trial of omicron-targeting COVID vaccine supports its use as a booster

8:11 am ET November 8, 2022 (MarketWatch)
Print

Novavax Inc. said Tuesday a late-stage trial of its vaccine targeting the COVID variant omicron supports its continued and future use as a booster. The company said the Phase 3 trial met its main strain-change endpoint. "The data demonstrate that the BA.1 vaccine candidate neutralizing responses in those not previously exposed to COVID-19 were greater than those of the prototype vaccine (NVX-CoV2373), enabling a shift to a new variant vaccine, if necessary," the company said in a statement. The prototype vaccine induced a broad immune response against the original coronavirus and BA.1 and BA.5 strains. "Today's results show that use of our prototype vaccine as a booster induces cross-reactive responses to a broad range of variants with the potential to protect against future strains," said Gregory M. Glenn, president of R&D at Novavax. Our vaccine, which provides broad immune response even in the face of evolving variants, presents a potential strategy to protect against COVID-19 now and into the future." Novavax shares fell 3.8% premarket and are down 86% in the year to date, while the S&P 500 has fallen 20%.

-Ciara Linnane

	

(END) Dow Jones Newswires

November 08, 2022 08:11 ET (13:11 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.